The Annapolis biotech firm touted its planned merger with the New York vaccine developer as one that would broaden its biodefense portfolio and put it on the fast track to becoming a public company.
But just seven months after announcing the merger, Siga suddenly pulled the plug. In an Oct. 4 press release, Siga officials said several factors played into the decision, such as the roughly $27 million in grants the company received for its smallpox and anti-viral programs. The...
| This story has expired! You can purchase the full text in our news archives. |
If you encounter other problems, please email nlundskow@capitalgazette.com and include your name, username, and any errors or messages that are displayed. The more information you can provide, the better able we will be to assist you.
In order to post or vote on a comment, you must be signed in with a hometownannapolis account.
Take a look at a summary of Commenting Guidelines.
If you encounter other problems, please email nlundskow@capitalgazette.com and include your name, username, and any errors or messages that are displayed. The more information you can provide, the better able we will be to assist you.